65,437 trials
Prescription Drug Insurance Decision Making
Primary: Count of Participants Whose 2017 Plan Differed From Their 2016 Plan — 85; 110; 86 Participants
Obstructive Sleep Apnea
Primary: Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 — 4.74; 9.08; 10.96; 12.99 minutes
Metastatic Colorectal Cancer (mCRC)
Primary: Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin® — 16500000; 16600000 ng.h/mL
Anxiety · Laceration Repair · Children
Primary: Observational Score Behavioral Distress Revised (OSBD-R) — 2.3; 0.8 units on a scale — p=0.98
Depression · End Stage Renal Disease
Primary: Number of Participants Who Initiated Depression Treatment — 57; 54 Participants — p=0.77
Myelofibrosis
Primary: Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement) — 14 Participants
Breast Cancer
Primary: Overall Safety — 12.6 percentage of participants
Social Acceptance
Primary: Bold Oxygen-level Dependent (BOLD) Activations in Prespecified ROIs — 0.117; 0.2545 BOLD signal — p=<.01
Recessive Dystrophic Epidermolysis Bullosa
Primary: Increased Expression of Full-length Type VII Collagen as Assessed by Immunofluorescence — 31.8; 28.4; 65.6 C7 Expression (percent of normal skin)
Chronic Low Back Pain
Primary: Low Back Pain After 6 Weeks of Intervention — 6.50; 6.00; 1.50; 3.50 units on a scale
Deglutition Disorders · Respiratory Distress Syndrome In Premature Infants · Respiratory Aspiration
Primary: Pharyngeal Phase Dysphagia — 7; 7 Participants
Cataract · Macular Degeneration
Primary: Number of Participants With Visually Significant Age-related Macular Degeneration (AMD) — 9; 12; 9; 12 Participants — p=0.52
Cardiac Arrest
Primary: Survival Rate - Number of Participants Alive — 55; 20; 32; 34 Participants — p=<0.001
COPD
Primary: Change in Lung Function (FEV1) — 0.05; -0.05 litres
Heart Failure
Primary: Change in Body Weight — -1.9; -1.9 kilogram